drugset / Trial / NCT03490786

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

NCT03490786

Phase 1 Completed 12 enrolled Gila Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Dose escalation study of GT-001

Timeline

Start
2017-07-16
Primary completion
2017-08-09
Completion
2017-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PEPTIDE YY HUMAN (3-36) Peptide 2.5 mg Topical

Indications